These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1658817)

  • 1. Ingestive behavior following central [D-Ala2, Leu5, Cys6]-enkephalin (DALCE), a short-acting agonist and long-acting antagonist at the delta opioid receptor.
    Arjune D; Bowen WD; Bodnar RJ
    Pharmacol Biochem Behav; 1991 Jun; 39(2):429-36. PubMed ID: 1658817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions.
    Ragnauth A; Ruegg H; Bodnar RJ
    Brain Res; 1997 Aug; 767(1):8-16. PubMed ID: 9365010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction by central beta-funaltrexamine of food intake in rats under freely-feeding, deprivation and glucoprivic conditions.
    Arjune D; Standifer KM; Pasternak GW; Bodnar RJ
    Brain Res; 1990 Dec; 535(1):101-9. PubMed ID: 1963340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective alterations in macronutrient intake of food-deprived or glucoprivic rats by centrally-administered opioid receptor subtype antagonists in rats.
    Koch JE; Bodnar RJ
    Brain Res; 1994 Sep; 657(1-2):191-201. PubMed ID: 7820618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central opioid receptor subtype antagonists differentially reduce intake of saccharin and maltose dextrin solutions in rats.
    Beczkowska IW; Koch JE; Bostock ME; Leibowitz SF; Bodnar RJ
    Brain Res; 1993 Aug; 618(2):261-70. PubMed ID: 8397050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different central opioid receptor subtype antagonists modify maltose dextrin and deprivation-induced water intake in sham feeding and sham drinking rats.
    Leventhal L; Bodnar RJ
    Brain Res; 1996 Nov; 741(1-2):300-8. PubMed ID: 9001736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of mu1 and mu2 opioid receptor subtypes in tail-pinch feeding in rats.
    Koch JE; Bodnar RJ
    Physiol Behav; 1993 Mar; 53(3):603-5. PubMed ID: 8383858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [D-Ala2,Leu5,Cys6]enkephalin: short-term agonist effects and long-term antagonism at delta opioid receptors.
    Calcagnetti DJ; Fanselow MS; Helmstetter FJ; Bowen WD
    Peptides; 1989; 10(2):319-26. PubMed ID: 2547203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta and kappa opioid receptor subtypes and ingestion: antagonist and glucoprivic effects.
    Yu WZ; Ruegg H; Bodnar RJ
    Pharmacol Biochem Behav; 1997 Mar; 56(3):353-61. PubMed ID: 9077569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of angiotensin II and hypertonic saline-induced drinking by opioid receptor subtype antagonists in rats.
    Ruegg H; Hahn B; Koch JE; Bodnar RJ
    Brain Res; 1994 Jan; 635(1-2):203-10. PubMed ID: 8173956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of the effect of the irreversible delta receptor antagonist [D-Ala2,Leu5,Cys6]-enkephalin on delta cx and delta ncx opioid binding sites in vitro and in vivo.
    Rothman RB; Bykov V; Jacobson AE; Rice KC; Long JE; Bowen WD
    Peptides; 1992; 13(4):691-4. PubMed ID: 1331996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site.
    Qi JA; Bowen WD; Mosberg HI; Rothman RB; Porreca F
    J Pharmacol Exp Ther; 1990 Nov; 255(2):636-41. PubMed ID: 2173752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress-induced tolerance to delta receptor agonist DPDPE and selectivity of the irreversible delta-ligand, DALCE.
    Calcagnetti DJ; Bowen WD; Holtzman SG
    Brain Res; 1990 Feb; 509(2):205-12. PubMed ID: 2157520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediation of insulin hyperphagia by specific central opiate receptor antagonists.
    Beczkowska IW; Bodnar RJ
    Brain Res; 1991 May; 547(2):315-8. PubMed ID: 1653080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
    Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central opioid receptor subtype mediation of isoproterenol-induced drinking in rats.
    Glass MJ; Hahn B; Joseph A; Bodnar RJ
    Brain Res; 1994 Sep; 657(1-2):310-4. PubMed ID: 7820634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mu-delta opioid interactions. III: Differential antagonism of DPDPE-induced increases in morphine EEG and EEG power spectra by DALCE and naltrindole.
    Stamidis H; Young GA
    Peptides; 1993; 14(3):511-7. PubMed ID: 8392719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats.
    Cole JL; Leventhal L; Pasternak GW; Bowen WD; Bodnar RJ
    Brain Res; 1995 Apr; 678(1-2):168-76. PubMed ID: 7620885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions.
    Bodnar RJ; Glass MJ; Ragnauth A; Cooper ML
    Brain Res; 1995 Nov; 700(1-2):205-12. PubMed ID: 8624711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central opioid receptor subtype antagonists differentially alter sucrose and deprivation-induced water intake in rats.
    Beczkowska IW; Bowen WD; Bodnar RJ
    Brain Res; 1992 Sep; 589(2):291-301. PubMed ID: 1327413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.